The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Keeping the Pressure on Congress: ACR Opposes Medicare Payment Adjustment Plan, Executive Order

Keeping the Pressure on Congress: ACR Opposes Medicare Payment Adjustment Plan, Executive Order

October 19, 2017 • By Angus Worthing, MD, FACP, FACR

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Greetings, advocates! Here’s a brief, interim hodgepodge of updates to keep you posted on government advocacy before the deluge of information swamps you in San Diego.

You Might Also Like
  • The ACR Opposes Part B Payment Demo & Other Highlights from the AMA HOD Meeting
  • ACR Talks to Congress about Physician Payment Reform
  • Frustrated by Congress, Trump Signs Order to Weaken Obamacare
Also By This Author
  • A Farewell Message from Outgoing Government Affairs Committee Chair Angus Worthing, MD, FACR, FACP

The Next Big Thing: Part B Drug Reimbursements
Medicare currently plans to adjust reimbursement of doctors in the MIPS program in 2019, not only based on E/M office services, but also on items provided to patients—including Part B drugs. The math just doesn’t work on this: getting the average sales price (ASP) + 6% reimbursement on thousands of dollars for pass-through drug costs, then being at risk for a 4% reduction of that whole drug cost. Then in 2022, there’s a risk of a 9% cut, setting up an absurd situation in which doctors would effectively be paying 3% of patients’ infusion bills back to Medicare. Congressional staff members were aware of this problem when the ACR Executive Committee visited them on the Hill in September, but they are waiting to see what the CMS does. It appears that Medicare will publish its final ruling on this by Nov. 1.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

To find out the thrilling next chapter in this story, saunter over to the advocacy sessions at the ACR/ARHP Annual Meeting on Sunday at 8:30 a.m. and Sunday at 1 p.m. (A member of Congress is scheduled to speak at this legislative and regulatory update session.) Meanwhile, your advocacy team has met with Congress, written letters through large coalitions and staged a large grassroots email campaign to get Congress to pressure Medicare to fix this. Stay tuned!

Biosimilars
With five FDA-approved rheumatology biosimilars in the U.S., now is the time to learn about this topic, and stay informed as the landscape changes. In San Diego, check out the Great Debate and other biosimilars sessions with Jonathan Kay, MD, a rheumatologist in Worcester, Mass., affiliated with UMass Memorial Medical Center, and Gene Huffstutter, MD, a practicing rheumatologist in Hixson, Tenn.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Also stay tuned for the ACR’s upcoming biosimilars white paper. Meanwhile, the U.S. marketplace is still waiting for the FDA to finalize the approval pathway for interchangeable biosimilars (Note: These are the ones that could be substituted at the pharmacy for the bio-originator you prescribe). The ACR’s wish list for the FDA and CMS includes meaningful suffixes, individual billing codes for reimbursement and labeling changes (e.g., to clearly state if a drug is a biosimilar and whether it is interchangeable; the addition of clinical data or a hyperlink to the data package).

Pages: 1 2 | Single Page

Filed Under: Legislation & Advocacy Tagged With: cost-sharing reduction, executive order, FDA-approved rheumatology biosimilars, Medicare payment adjustment plan, Merit-Based Incentive Payment System (MIPS), Part B drugs, reduced insurance restrictions, Washington D.C. update

You Might Also Like:
  • The ACR Opposes Part B Payment Demo & Other Highlights from the AMA HOD Meeting
  • ACR Talks to Congress about Physician Payment Reform
  • Frustrated by Congress, Trump Signs Order to Weaken Obamacare
  • Possible MIPS Errors in 2019 Payment Adjustment

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)